KDR and prostate carcinoma: Cabozantinib is an orally bioavailable small molecule inhibitor of c-Met, RET, ROS1, Alk, VEGFR2, and TRK receptors with approved uses for the treatment of metastatic medullary thyroid cancer, prostate cancer and advanced renal cell carcinoma [39].